JP2013507352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507352A5 JP2013507352A5 JP2012532683A JP2012532683A JP2013507352A5 JP 2013507352 A5 JP2013507352 A5 JP 2013507352A5 JP 2012532683 A JP2012532683 A JP 2012532683A JP 2012532683 A JP2012532683 A JP 2012532683A JP 2013507352 A5 JP2013507352 A5 JP 2013507352A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- composition according
- propargyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims description 21
- RUOKEQAAGRXIBM-UHFFFAOYSA-N n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(NCC#C)CCC2=C1 RUOKEQAAGRXIBM-UHFFFAOYSA-N 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- 206010003591 Ataxia Diseases 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 208000019505 Deglutition disease Diseases 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 206010047571 Visual impairment Diseases 0.000 claims description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical group CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 2
- JDBJJCWRXSVHOQ-UHFFFAOYSA-N methanesulfonic acid;n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound CS(O)(=O)=O.C1=CC=C2C(NCC#C)CCC2=C1 JDBJJCWRXSVHOQ-UHFFFAOYSA-N 0.000 claims description 2
- 230000001144 postural effect Effects 0.000 claims description 2
- 208000027765 speech disease Diseases 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 208000029257 vision disease Diseases 0.000 claims description 2
- 230000004393 visual impairment Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 238000000034 method Methods 0.000 description 13
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940001133 rasagiline 1 mg Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27867709P | 2009-10-09 | 2009-10-09 | |
| US61/278,677 | 2009-10-09 | ||
| PCT/IB2010/002852 WO2011042812A1 (en) | 2009-10-09 | 2010-10-08 | Use of rasagiline for the treatment of progressive supranuclear palsy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013507352A JP2013507352A (ja) | 2013-03-04 |
| JP2013507352A5 true JP2013507352A5 (enExample) | 2013-11-28 |
Family
ID=43533485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012532683A Pending JP2013507352A (ja) | 2009-10-09 | 2010-10-08 | 進行性核上性麻痺の治療のためのラサギリンの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110130466A1 (enExample) |
| EP (1) | EP2485722A1 (enExample) |
| JP (1) | JP2013507352A (enExample) |
| AU (1) | AU2010304755A1 (enExample) |
| CA (1) | CA2777185A1 (enExample) |
| IL (1) | IL218948A0 (enExample) |
| WO (1) | WO2011042812A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2371883T3 (es) * | 2004-11-24 | 2012-01-11 | Teva Pharmaceutical Industries Ltd. | Composiciones de rasagilina de disgregación oral. |
| CA2643235C (en) * | 2006-02-21 | 2014-06-17 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| MX2008012781A (es) * | 2006-04-03 | 2008-10-14 | Teva Pharma | Uso de rasagilina para el tratamiento de sindrome de piernas inquietas. |
| EP1892233A1 (de) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| EA016820B1 (ru) * | 2006-12-14 | 2012-07-30 | Тева Фармасьютикал Индастриз, Лтд. | Кристаллическое твердое основание разагилина |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| AU2008296908B2 (en) * | 2007-09-05 | 2014-01-09 | Teva Pharmaceutical Industries, Ltd. | Method of treating glaucoma using rasagiline |
| AU2009204454B2 (en) * | 2008-01-11 | 2015-02-05 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations, their preparation and use |
| JP2011524353A (ja) * | 2008-06-10 | 2011-09-01 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリン軟ゼラチンカプセル |
| MX2010013766A (es) * | 2008-06-13 | 2011-03-15 | Teva Pharmaceutical Ind Ltd Star | Rasagilina para modificacion de enfermedad de parkinson. |
| US8334409B2 (en) * | 2008-06-19 | 2012-12-18 | Teva Pharmaceutical Industries, Ltd. | Process for purifying rasagiline base |
| AU2009260728B2 (en) * | 2008-06-19 | 2015-01-29 | Teva Pharmaceutical Industries, Ltd. | Process for preparing and drying solid rasagiline base |
| US20100189788A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline base formulation |
| CA2767592A1 (en) | 2009-07-09 | 2011-01-13 | Ratiopharm Gmbh | Salts of rasagiline and pharmaceutical preparations thereof |
| EP2515891A4 (en) * | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-keto-N-propargyl-1-aminoindan |
| JP2013537530A (ja) | 2010-07-27 | 2013-10-03 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンシトレートの分散物 |
| EP2603212A4 (en) | 2010-07-27 | 2014-01-08 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER |
| BR112014008552A2 (pt) | 2011-10-10 | 2017-04-18 | Teva Pharma | r(+)-n-metil-propargilaminoindano |
| AU2012323349A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | R(+)-N-formyl-propargyl-aminoindan |
| TW201412304A (zh) | 2012-08-17 | 2014-04-01 | Teva Pharma | 瑞沙吉林之非經腸調配物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2371883T3 (es) * | 2004-11-24 | 2012-01-11 | Teva Pharmaceutical Industries Ltd. | Composiciones de rasagilina de disgregación oral. |
| BRPI0709033A2 (pt) * | 2006-03-29 | 2011-06-21 | Velacor Therapeutics Pty Ltd | composição farmacêutica, métodos de tratamento ou prevenção de doença neurodegenerativa numa pessoa, de inibição ou redução da fosforilação de uma proteìna tau num neurÈnio, célula glial ou corpo de lewy, de intensificação da atividade de pp2a e de inibição da atividade de gsk3 num neurÈnio ou célula glial e uso de selenato ou sal farmaceuticamamente aceitável do mesmo |
| EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| WO2009054544A1 (en) * | 2007-10-26 | 2009-04-30 | Eisai R & D Management Co., Ltd. | Ampa receptor antagonists for parkinson's disease and movement disorders |
| US8334409B2 (en) * | 2008-06-19 | 2012-12-18 | Teva Pharmaceutical Industries, Ltd. | Process for purifying rasagiline base |
| AU2009260728B2 (en) * | 2008-06-19 | 2015-01-29 | Teva Pharmaceutical Industries, Ltd. | Process for preparing and drying solid rasagiline base |
| DE102008064061A1 (de) * | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Feste Zusammensetzung mit dem Wirkstoff Rasagilin |
| US20100189788A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline base formulation |
| JP2013537530A (ja) * | 2010-07-27 | 2013-10-03 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンシトレートの分散物 |
| EP2603212A4 (en) * | 2010-07-27 | 2014-01-08 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER |
| PH12013500821A1 (en) * | 2010-10-26 | 2019-07-03 | Teva Pharma | Deuterium enriched rasagiline |
| EA201490756A1 (ru) * | 2011-10-10 | 2014-09-30 | Тева Фармасьютикал Индастриз, Лтд. | Разагилина цитрамид |
| BR112014008552A2 (pt) * | 2011-10-10 | 2017-04-18 | Teva Pharma | r(+)-n-metil-propargilaminoindano |
| AU2012323349A1 (en) * | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | R(+)-N-formyl-propargyl-aminoindan |
-
2010
- 2010-10-08 CA CA2777185A patent/CA2777185A1/en not_active Abandoned
- 2010-10-08 WO PCT/IB2010/002852 patent/WO2011042812A1/en not_active Ceased
- 2010-10-08 AU AU2010304755A patent/AU2010304755A1/en not_active Abandoned
- 2010-10-08 EP EP10785198A patent/EP2485722A1/en not_active Withdrawn
- 2010-10-08 JP JP2012532683A patent/JP2013507352A/ja active Pending
- 2010-10-08 US US12/901,281 patent/US20110130466A1/en not_active Abandoned
-
2012
- 2012-03-29 IL IL218948A patent/IL218948A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507352A5 (enExample) | ||
| JP2013533287A5 (enExample) | ||
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2015515985A5 (enExample) | ||
| EA201390827A1 (ru) | Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом | |
| AR124500A2 (es) | Aumento de la biodisponibilidad de droga en terapia naltrexona | |
| NZ589445A (en) | Rasagiline for parkinson's disease modification | |
| JP2011225596A5 (enExample) | ||
| JP2005506370A5 (enExample) | ||
| JP2016163571A5 (enExample) | ||
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| NZ597378A (en) | Treatment of multiple sclerosis with laquinimod | |
| JP2011516417A5 (enExample) | ||
| JP2014526503A5 (enExample) | ||
| RU2013108258A (ru) | Применение разагилина для лечения обонятельной дисфункции | |
| JP2011528333A5 (enExample) | ||
| JP2013509411A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| PE20081106A1 (es) | Comprimidos pediatricos de capecitabina | |
| JP2016512817A5 (enExample) | ||
| JP2014508758A5 (enExample) | ||
| JP2014524478A5 (enExample) | ||
| JP2008534503A5 (enExample) | ||
| JP2010500284A5 (enExample) |